Johnson & Johnson's single-shot coronavirus vaccine has begun human trials

Henrietta Strickland
August 1, 2020

Displaying its Soviet-era like competitive spirit during the Coronavirus crisis, Russian Federation is reportedly aiming to approve its COVID-19 vaccine before mid-August for wider public use. The mRNA vaccine developed from Moderna and Pfizer needs two doses of vaccine to get the expected results, but in the J&J preclinical study, the single-shot vaccine is enough to impart immunity.

While some global vaccines have entered the third phase of trials, the Russian vaccine is yet to complete its second phase, which the developers plan to complete by August 3. "The trials began under the supervision of physician Dr Ajit Pratap Singh and gynaecologist and obstetrician Dr Sona Ghosh and the vaccine has been administered to 9 volunteers so far", Chief Administrative Officer of the hospital, Venketesh Chaturvedi said.

The Russian officials are working towards a date of August 10 or earlier for approval of the vaccine, which has been prepared by the Moscow-based Gamaleya Institute.

"The Ministry of Health in Russian Federation is following all necessary strict procedures".

"Russia will have got there first", Mr Dmitriev told CNN, likening the Russian coronavirus research to the successful launch of the world's first satellite by the Soviet Union in 1957. "No corners are being cut", Dmitriev said on Tuesday.

Some vaccines trials are in their third phase, while Russia's has not completed its second, CNN noted.

Russian scientists explain they have moved quickly because their vaccine is built on an existing vaccine.

"We showed a single immunization of the Ad26 COVID-19 vaccine induces neutralizing antibody response protection", said Dan H. Barouch, M.D., Ph.D., the director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center. The allegations have been denied by Moscow.

Ms Golikova's remarks follow a CNN interview with the head of Russia's sovereign welfare fund that bankrolls research and development for the coronavirus vaccine at the Gamalei Institute of Epidemiology and Microbiology. At least four are in final Phase III human trials, according to World Health Organization data - including three developed in China and another in Britain. We hope that we have succeeded by giving you the full details and information.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER